ReviewFrontiers in bioengineering and biotechnology2025
Nanocarrier-mediated drug delivery systems for spinal cord injury treatment.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reprogramming the oxidative microenvironment: Antioxidant nanoplatforms for central nervous system repair.Materials today. Bio · 2026Review
- ROS-Responsive Trifluoperazine Prodrug Nanoparticles and Mesenchymal Stem Cell Exosomes Synergistically Modulate Astrocyte Phenotype for Spinal Cord Injury Repair.ACS applied materials & interfaces · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury is a severe neurological condition that frequently. Results in lasting motor and sensory dysfunction. Traditional drug therapies have shown limited efficacy in addressing the complexities of spinal cord injury. This limitation highlighting the urgent need for innovative treatment strategies. In recent years, nanocarrier-mediated systems have garnered significant attention due to their superior drug delivery capabilities and targeting precision. This review summarizes the latest advancements in the application of nanocarriers for the treatment of spinal cord injuries, discussing various types of nanocarriers, drug loading and capacity and release profiles, as well as targeted delivery strategies. The insights aim to establish a theoretical foundation for future research and clinical applications in this critical area of medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.